CN1778294A - 紫铆素及其衍生物在制备色素代谢疾病药物的用途 - Google Patents
紫铆素及其衍生物在制备色素代谢疾病药物的用途 Download PDFInfo
- Publication number
- CN1778294A CN1778294A CN 200410091322 CN200410091322A CN1778294A CN 1778294 A CN1778294 A CN 1778294A CN 200410091322 CN200410091322 CN 200410091322 CN 200410091322 A CN200410091322 A CN 200410091322A CN 1778294 A CN1778294 A CN 1778294A
- Authority
- CN
- China
- Prior art keywords
- butin
- medicine
- melanocyte
- derivant
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MJBPUQUGJNAPAZ-AWEZNQCLSA-N butin Chemical compound C1([C@@H]2CC(=O)C3=CC=C(C=C3O2)O)=CC=C(O)C(O)=C1 MJBPUQUGJNAPAZ-AWEZNQCLSA-N 0.000 title claims abstract description 89
- MJBPUQUGJNAPAZ-UHFFFAOYSA-N Butine Natural products O1C2=CC(O)=CC=C2C(=O)CC1C1=CC=C(O)C(O)=C1 MJBPUQUGJNAPAZ-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims description 7
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 208000016097 disease of metabolism Diseases 0.000 title 1
- 239000000049 pigment Substances 0.000 claims abstract description 8
- 210000000987 immune system Anatomy 0.000 claims abstract description 6
- 206010049865 Achromotrichia acquired Diseases 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 201000001441 melanoma Diseases 0.000 claims abstract description 4
- 210000002752 melanocyte Anatomy 0.000 claims description 22
- 241001597008 Nomeidae Species 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000036564 melanin content Effects 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 229930182478 glucoside Natural products 0.000 claims description 2
- -1 glucoside compound Chemical class 0.000 claims description 2
- 238000009395 breeding Methods 0.000 claims 1
- 230000001488 breeding effect Effects 0.000 claims 1
- 206010024380 Leukoderma Diseases 0.000 abstract 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 12
- 241000700199 Cavia porcellus Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 206010047642 Vitiligo Diseases 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 102000003425 Tyrosinase Human genes 0.000 description 6
- 108060008724 Tyrosinase Proteins 0.000 description 6
- 108700005078 Synthetic Genes Proteins 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 229940027041 8-mop Drugs 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000002780 melanosome Anatomy 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000010219 correlation analysis Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- AYMYWHCQALZEGT-ORCRQEGFSA-N butein Chemical compound OC1=CC(O)=CC=C1C(=O)\C=C\C1=CC=C(O)C(O)=C1 AYMYWHCQALZEGT-ORCRQEGFSA-N 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000288027 Chrysolophus pictus Species 0.000 description 1
- 240000003707 Coreopsis basalis Species 0.000 description 1
- 244000128583 Coreopsis cardaminifolia Species 0.000 description 1
- 235000005912 Coreopsis cardaminifolia Nutrition 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 241000132539 Cosmos Species 0.000 description 1
- 241000843054 Cosmos sulphureus Species 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- SXFPNMRWIWIAGS-UHFFFAOYSA-N Khellin Natural products COC1C2CCOC2C(OC)C3OC(C)CC(=O)C13 SXFPNMRWIWIAGS-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 238000009193 PUVA therapy Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000145469 Vernonia anthelmintica Species 0.000 description 1
- 235000013018 Vernonia anthelmintica Nutrition 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 238000002419 base digestion Methods 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 230000004345 fruit ripening Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- HSMPDPBYAYSOBC-UHFFFAOYSA-N khellin Chemical compound O1C(C)=CC(=O)C2=C1C(OC)=C1OC=CC1=C2OC HSMPDPBYAYSOBC-UHFFFAOYSA-N 0.000 description 1
- 229960002801 khellin Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000004511 skin melanocyte Anatomy 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410091322 CN1778294B (zh) | 2004-11-23 | 2004-11-23 | 紫铆素及其衍生物在制备色素代谢疾病药物的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410091322 CN1778294B (zh) | 2004-11-23 | 2004-11-23 | 紫铆素及其衍生物在制备色素代谢疾病药物的用途 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2008101721967A Division CN101559051A (zh) | 2004-11-23 | 2004-11-23 | 紫铆素及其衍生物在制备具有抑制黑色素瘤作用药物的用途 |
CNA2008101721952A Division CN101559050A (zh) | 2004-11-23 | 2004-11-23 | 紫铆素及其衍生物在制备具有抑制免疫系统作用药物的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1778294A true CN1778294A (zh) | 2006-05-31 |
CN1778294B CN1778294B (zh) | 2010-12-08 |
Family
ID=36768832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410091322 Expired - Fee Related CN1778294B (zh) | 2004-11-23 | 2004-11-23 | 紫铆素及其衍生物在制备色素代谢疾病药物的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1778294B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102627623A (zh) * | 2012-03-20 | 2012-08-08 | 中国科学院新疆理化技术研究所 | 从驱虫斑鸠菊果实中制备紫铆素的方法 |
CN104523796A (zh) * | 2014-12-22 | 2015-04-22 | 新疆大学 | 两色金鸡菊提取物作为制备治疗白癜风药物的应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105801509B (zh) * | 2016-05-03 | 2018-01-05 | 中国科学院新疆理化技术研究所 | 一种查尔酮衍生物的制备方法和用途 |
-
2004
- 2004-11-23 CN CN 200410091322 patent/CN1778294B/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102627623A (zh) * | 2012-03-20 | 2012-08-08 | 中国科学院新疆理化技术研究所 | 从驱虫斑鸠菊果实中制备紫铆素的方法 |
CN104523796A (zh) * | 2014-12-22 | 2015-04-22 | 新疆大学 | 两色金鸡菊提取物作为制备治疗白癜风药物的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1778294B (zh) | 2010-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1742980A (zh) | 新生儿退黄中药洗液 | |
CN107868068B (zh) | 一类乌药烷型二聚倍半萜类化合物、其制备方法及用途 | |
CN1686506A (zh) | 一种治疗乳腺增生疾病的药物和制备方法及其应用 | |
CN101057855A (zh) | 含淫羊藿有效成分的药物组合物及其用途 | |
CN106008543A (zh) | 一种新的二萜类化合物及其制备方法 | |
CN101485694B (zh) | 一种灵芝三萜类成分的提取方法 | |
CN1182851C (zh) | 一种从抗流感病毒有效部位中提取的化合物 | |
CN1778294A (zh) | 紫铆素及其衍生物在制备色素代谢疾病药物的用途 | |
CN1778324A (zh) | 驱虫斑鸠菊有效部位及其制备方法和用途 | |
CN101396373B (zh) | 一种华蟾素提取物及其制备方法 | |
CN102362877B (zh) | 一种雾水葛提取物的应用 | |
CN101559050A (zh) | 紫铆素及其衍生物在制备具有抑制免疫系统作用药物的用途 | |
CN1261143C (zh) | 抗流感病毒的药物有效部位及活性成分的分离制备方法 | |
CN101559051A (zh) | 紫铆素及其衍生物在制备具有抑制黑色素瘤作用药物的用途 | |
CN101565443B (zh) | 新冷杉三萜内酯类化合物及其制备方法和应用 | |
CN1907312A (zh) | 鹅不食草挥发油在制备肿瘤生长和增殖的抑制剂中的应用 | |
CN106117034A (zh) | 一种高度氧化的倍半萜类化合物及其制备方法和医药用途 | |
CN1931347A (zh) | 一种治疗慢性肝炎的药物及制备方法和质量控制方法 | |
CN102114047B (zh) | 通过胃蛋白酶和胰蛋白酶联合酶解的土鳖虫冻干粉1和2及其用途 | |
CN1827091A (zh) | 包含补骨脂酚的用于治疗妇女乳癌的医药组合物 | |
CN1139387C (zh) | 淫羊藿多糖及其制备方法和该多糖在制备提高机体免疫功能药物中的应用 | |
CN1872101A (zh) | 具抗病毒作用的小紫金牛提取物及其提取方法和应用 | |
CN101053587A (zh) | 一种用于抗肿瘤的药物组合物及制备方法和质量控制方法 | |
CN1386526A (zh) | 一种治疗心脑血管疾病的中药药物组合物及其制备方法 | |
CN101028311A (zh) | 中药卷柏的新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NANJING RUIJING MEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SHANG JING Effective date: 20131209 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 211198 NANJING, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131209 Address after: 211198, Nanjing Road, Jiangning District, Jiangsu, 18 (Jiangning Science Park) Patentee after: Nanjing Ruijing Medical Technology Co., Ltd. Address before: Tong Xiang Nanjing city Jiangsu province 210009 No. 24 China Medicine University Center for drug screening Patentee before: Shang Jing |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101208 Termination date: 20191123 |